Drug intelligence / Profile preview

quinalizarin

Development stage
Unknown
Modality
Small Molecules
01

Overview

Quinalizarin is a tetrahydroxyanthraquinone compound with the chemical formula C14H8O6 and molecular weight of approximately 272.21 g/mol[3][6][10]. It is known for its deep red to purple color and is used as a dye and pigment in various applications[10]. In pharmacology and biomedical research, quinalizarin acts as a potent and selective inhibitor of protein kinase CK2 (casein kinase II), affecting cell proliferation, migration, and apoptosis in cancer cells[4][9]. It has demonstrated anticancer activity by inducing apoptosis through modulation of signaling pathways such as MAPK (mitogen-activated protein kinase), STAT3 (signal transducer and activator of transcription 3), Akt (protein kinase B), and p53[4][5][9]. Additionally, quinalizarin exhibits antifungal properties against Candida albicans by inhibiting hyphal growth and biofilm formation via mechanisms involving reactive oxygen species generation and mitochondrial membrane potential disruption[1][5].

Other names
1,2,5,8-tetrahydroxyanthraquinone1,2,5,8-tetrahydroxyanthracene-9,10-dionealizarin bordeaux Balizarine bordeaux bC.I. Mordant Violet 26C.I. 58500
02

Targets

CK2 (Casein kinase II subunit alpha)

Beyond the preview

Go deeper on quinalizarin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on quinalizarin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call